Latest ArticlesEN-USSun, 02 Aug 2015 18:10:09 -040020150724-00014 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CCtbhf_2Zas/gsk-malaria-vaccine-containing-agenusqs21-stimulon-gets-positive-chmp-opinion-20150724-00014
GSK'' Malaria Vaccine Containing Agenus''QS-21 Stimulon Gets Positive CHMP OpinionGSK'' Malaria Vaccine Containing Agenus''QS-21 Stimulon Gets Positive CHMP Opinion<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/CCtbhf_2Zas" height="1" width="1" alt=""/>Fri, 24 Jul 2015 01:17:00 Z2015-07-24T01:17:00Zhttp://www.nasdaq.com/article/gsk-malaria-vaccine-containing-agenusqs21-stimulon-gets-positive-chmp-opinion-20150724-00014499851http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FyHcHaunLVE/agenus-agen-reports-wider-than-expected-q2-loss-tale-of-the-tape-cm499851
Agenus (AGEN) Reports Wider-than-Expected Q2 Loss - Tale of the TapeAgenus Inc. ( AGEN ) is a Lexington, MA based development stage company focused on developing immunotherapies for cancer and other diseases. With no approved products in its portfolio, Agenus' revenues consist of fees earned under license agreements with<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/FyHcHaunLVE" height="1" width="1" alt=""/>Thu, 23 Jul 2015 15:33:13 Z2015-07-23T15:33:13Zhttp://www.nasdaq.com/article/agenus-agen-reports-wider-than-expected-q2-loss-tale-of-the-tape-cm499851499061http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uNLHjNr9Ogs/will-agenus-agen-disappoint-investors-this-earnings-analyst-blog-cm499061
Will Agenus (AGEN) Disappoint Investors this Earnings? - Analyst BlogAgenus Inc.AGEN is scheduled to report second quarter 2015 results on Jul 23, 2015. Although the company doesn't have an impressive track record with a four quarter average negative earnings surprise of 12.59%, let's see how things are shaping<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/uNLHjNr9Ogs" height="1" width="1" alt=""/>Tue, 21 Jul 2015 20:31:42 Z2015-07-21T20:31:42Zhttp://www.nasdaq.com/article/will-agenus-agen-disappoint-investors-this-earnings-analyst-blog-cm499061497848http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/05T9vpffM4A/these-2-stocks-doubled-in-2015-is-1-still-a-buy-cm497848
These 2 Stocks Doubled in 2015 -- Is 1 Still a Buy?With 2015 halfway over, it's a good time to take a look at the best performing stocks so far and consider if they remain compelling buys heading into the back end of the year. Among<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/05T9vpffM4A" height="1" width="1" alt=""/>Sat, 18 Jul 2015 16:26:41 Z2015-07-18T16:26:41Zhttp://www.nasdaq.com/article/these-2-stocks-doubled-in-2015-is-1-still-a-buy-cm497848491595http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xhCOgMTY-H0/why-agenus-agen-could-be-positioned-for-a-surge-tale-of-the-tape-cm491595
Why Agenus (AGEN) Could Be Positioned for a Surge? - Tale of the TapeAgenus Inc. ( AGEN ) is an immunotherapy company that could be an interesting play for investors. That is because, not only does the stock have decent short term momentum, but it is seeing solid activity on the earnings<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/xhCOgMTY-H0" height="1" width="1" alt=""/>Mon, 29 Jun 2015 14:35:00 Z2015-06-29T14:35:00Zhttp://www.nasdaq.com/article/why-agenus-agen-could-be-positioned-for-a-surge-tale-of-the-tape-cm49159520150617-00299 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KEUej0-7s3M/agenus-appoints-evan-ballantyne-as-cfo-20150617-00299
Agenus Appoints Evan Ballantyne As CFOAgenus Appoints Evan Ballantyne As CFO<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/KEUej0-7s3M" height="1" width="1" alt=""/>Wed, 17 Jun 2015 07:59:00 Z2015-06-17T07:59:00Zhttp://www.nasdaq.com/article/agenus-appoints-evan-ballantyne-as-cfo-20150617-00299484287http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DqDxz4Zq3OU/cancer-drugs-2-stocks-to-watch-cm484287
Cancer Drugs: 2 Stocks to WatchThe treatment of cancer is undergoing a potential revolution with the advent of powerful new immunotherapies and small molecule, all oral treatments. The ultimate goal is to develop chemotherapy free treatment regimens that are more<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/DqDxz4Zq3OU" height="1" width="1" alt=""/>Sun, 07 Jun 2015 18:21:19 Z2015-06-07T18:21:19Zhttp://www.nasdaq.com/article/cancer-drugs-2-stocks-to-watch-cm484287483657http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UrlyDjRXNQY/agenus-gains-after-merck-extends-immuno-oncology-ties-analyst-blog-cm483657
Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst BlogAgenus Inc. 's AGEN shares were up 4% on the extension of its existing collaboration and license agreement with Merck MRK for the discovery and development of therapeutic antibodies to Merck's proprietary immune checkpoints for the treatment of cancer.<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/UrlyDjRXNQY" height="1" width="1" alt=""/>Thu, 04 Jun 2015 20:25:37 Z2015-06-04T20:25:37Zhttp://www.nasdaq.com/article/agenus-gains-after-merck-extends-immuno-oncology-ties-analyst-blog-cm483657477453http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_c0-Sp9dLM0/agenus-agen-provides-update-on-its-brain-cancer-vaccine-analyst-blog-cm477453
Agenus (AGEN) Provides Update on its Brain Cancer Vaccine - Analyst BlogAgenus Inc.AGEN announced data on continuing survival from a phase II study on its cancer vaccine candidate, prophage, which is being developed for the treatment of glioblastoma multiforme (GBM). The data from the study will be presented orally at<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/_c0-Sp9dLM0" height="1" width="1" alt=""/>Fri, 15 May 2015 21:58:32 Z2015-05-15T21:58:32Zhttp://www.nasdaq.com/article/agenus-agen-provides-update-on-its-brain-cancer-vaccine-analyst-blog-cm477453470152http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SA9B1q3s3k4/why-agenus-inc-shares-surged-higher-in-early-trading-today-cm470152
Why Agenus Inc. Shares Surged Higher In Early Trading TodaySource Agenus Although we don't believe intiming the market or panicking over market movements, we do like to keep an eye on big changes just in<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/SA9B1q3s3k4" height="1" width="1" alt=""/>Tue, 28 Apr 2015 16:22:40 Z2015-04-28T16:22:40Zhttp://www.nasdaq.com/article/why-agenus-inc-shares-surged-higher-in-early-trading-today-cm470152469153http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4FBbVSyWtNM/why-agenus-inc-shares-are-soaring-today-cm469153
Why Agenus Inc. Shares Are Soaring TodayAlthough we don't believe intiming the market or panicking over market movements, we do like to keep an eye on big changes just in case they're material to our investing thesis.<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/4FBbVSyWtNM" height="1" width="1" alt=""/>Fri, 24 Apr 2015 19:22:39 Z2015-04-24T19:22:39Zhttp://www.nasdaq.com/article/why-agenus-inc-shares-are-soaring-today-cm469153468675http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GWZEFR6eseM/eli-lilly-beats-on-1q-earnings-by-wide-margin-affirms-view-analyst-blog-cm468675
Eli Lilly Beats on 1Q Earnings by Wide Margin, Affirms View - Analyst BlogEli Lilly & CompanyLLY reported first quarter 2015 adjusted earnings per share of 87 cents, well above the Zacks Consensus Estimate of 76 cents per share and 18% above the year ago earnings. First quarter revenues slipped 1% to<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/GWZEFR6eseM" height="1" width="1" alt=""/>Thu, 23 Apr 2015 17:23:44 Z2015-04-23T17:23:44Zhttp://www.nasdaq.com/article/eli-lilly-beats-on-1q-earnings-by-wide-margin-affirms-view-analyst-blog-cm468675468502http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/upsnkOVNwm8/agenus-agen-reports-wider-than-expected-q1-loss-tale-of-the-tape-cm468502
Agenus (AGEN) Reports Wider-than-Expected Q1 Loss - Tale of the TapeAgenus Inc. ( AGEN ) focuses on developing immuno oncology drugs. This Massachusetts based company is well known for developing cancer vaccines and adjuvants. The company does not have any approved product and revenues include payment received from partners<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/upsnkOVNwm8" height="1" width="1" alt=""/>Thu, 23 Apr 2015 13:23:46 Z2015-04-23T13:23:46Zhttp://www.nasdaq.com/article/agenus-agen-reports-wider-than-expected-q1-loss-tale-of-the-tape-cm468502468274http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fJkSEJMqk6A/will-agenus-agen-disappoint-in-q1-earning-season-analyst-blog-cm468274
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst BlogAgenus Inc.AGEN is expected to report first quarter 2015 results on Apr 23. Last quarter, the company had posted a negative earnings surprise of 20%. Let's see how things are shaping up for this announcement.Factors at Play Agenus posted<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/fJkSEJMqk6A" height="1" width="1" alt=""/>Wed, 22 Apr 2015 20:22:24 Z2015-04-22T20:22:24Zhttp://www.nasdaq.com/article/will-agenus-agen-disappoint-in-q1-earning-season-analyst-blog-cm468274467941http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zmRqCRAPcsY/is-immuno-oncology-the-best-area-of-biotech-to-invest-in-right-now-cm467941
Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?Biotechnology is rapidly giving rise to ground breaking new medicines that are dramatically changing the outlook for devastating diseases such as hepatitis C, malaria, and, perhaps most astoundingly, cancer. This innovation boom has gone hand<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/zmRqCRAPcsY" height="1" width="1" alt=""/>Wed, 22 Apr 2015 13:21:57 Z2015-04-22T13:21:57Zhttp://www.nasdaq.com/article/is-immuno-oncology-the-best-area-of-biotech-to-invest-in-right-now-cm467941467955http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-uIIeDn6rc/will-agenus-agen-continue-to-surge-higher-tale-of-the-tape-cm467955
Will Agenus (AGEN) Continue to Surge Higher? - Tale of the TapeAs of late, it has definitely been a great time to be an investor Agenus Inc ( AGEN ) . The stock has moved higher by 11.2% in the past month, while it is also above its 20 Day<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/C-uIIeDn6rc" height="1" width="1" alt=""/>Wed, 22 Apr 2015 12:21:41 Z2015-04-22T12:21:41Zhttp://www.nasdaq.com/article/will-agenus-agen-continue-to-surge-higher-tale-of-the-tape-cm467955466747http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q1K2lc2lOc8/3-stocks-that-could-double-your-money-cm466747
3 Stocks That Could Double Your MoneyIf you're looking for a shot at doubling an investment, you'll want to take a look at the biotech industry. Biotech companies have been some of the best performing stocks over the last couple of<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Q1K2lc2lOc8" height="1" width="1" alt=""/>Sun, 19 Apr 2015 15:47:40 Z2015-04-19T15:47:40Zhttp://www.nasdaq.com/article/3-stocks-that-could-double-your-money-cm466747